A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

Abroad (travel likely)RecruitingPHASE2

Conditions

Cervical Cancer · Ovarian Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shandong Cancer Hospital, Ji'nan, Shandong, China
Contact: Study coordinator (Jinming Yu, Dr.) · sdyujinming@126.com · Shandong Cancer Hospital
Contact: Principal Investigator (Jinming Yu, Dr.)

Study leads

Jinming Yu, Dr.
Principal Investigator
Shandong Cancer Hospital and Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Breast Cancer · Endometrial Cancer · Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Orlando, United States · Boston, United States

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Differentiated Thyroid Cancer · Pediatric Cancer · Cancer

Abroad (travel likely)RecruitingPHASE2

San Francisco, United States · Philadelphia, United States

ASk Questions in GYnecologic Oncology (ASQ-GYO)

Ovarian Cancer · Endometrial Cancer · Cervical Cancer

Abroad (travel likely)Recruiting

Detroit, United States

NYSCF Scientific Discovery Biobank

ALS · Amyotrophic Lateral Sclerosis · Alzheimer Disease

Abroad (travel likely)Recruiting

New York, United States